Covid Vaccines Reducing Infections

In summary, the Covid vaccine does reduce the severity and death rate - no question. However, the claim is that it does nothing to slow the spread. This is exacerbated by some studies show 90% of people who have it do not even know it. If you don't know you have it, you don't isolate and keep spreading it. The vaccines do reduce transmission by reducing the time you are infectious. So, it is not only a good idea for your health to get vaccinated and get a booster every year - conveniently, it could be done when you get the flu shot - maybe in the same vaccine. For high-risk groups like me and my doctor without going into why he is at high risk, my doctor recommends a
  • #36
Rive said:
Sure. Worked. But, sadly, that won't have much prediction power regarding the future.

Those lines are converging back to the baseline there: some assessment will be needed to check if it's a general trend, or just the relevance of the available boosters gone as new strains emerged: whether we could get back that 'work' with updated boosters...

With the best available one here is 'up to date' (:rolleyes:) against Omicron only, what do you think about the efficiency I can expect?
How is Covid the same and different than the flu?
Are there different strains? Yes.
Are some strains worse than others? Yes
Are new strains expected to emerge? Yes

So in response to your comments and question, I would say it's not much different than the flu, other than it's a lot deadlier. Correct me if I'm wrong, but it sounds like you expect the Covid vaccines to work like the Polio or Small Pox vaccines, where they seem to provide decades long immunity. (This article in Scientific American seems to imply that we have no idea how long a Small Pox vaccine is good for.)

I would be interested to see what other similarities and dissimilarities there are between the various bugs and our vaccines to combat them. Does anyone know how long an H1N1 vaccine lasts for the average person?
 
  • Like
Likes symbolipoint, russ_watters and BillTre
Biology news on Phys.org
  • #37
OmCheeto said:
How is Covid the same and different than the flu?
Compared to Covid, flu seems to work on a steady, slow, clockwork schedule, so we can casually pick a strain at spring to roll out a vaccine against it at autumn.

For Covid, we already know that the strain picked might be even extinct by the time the vaccine will be available and we can only hope for cross-immunity for its descendants to remain adequate/useful.
Though we also know, that one of the key points for a descendant strain to grow prevalent is to be able to at least partially bypass the immunity present in the population...

OmCheeto said:
Correct me if I'm wrong, but it sounds like you expect
You are wrong. I do know for a long time that it won't be like that.

Also, what I expect is questions to be raised and answers sought instead of (false) confidence. See:
Rive said:
Regarding boosters, at this point I think we need to wait for some comprehensive studies adjusted for new strains versus multivalent boosters.

With the actual who-knows-how-many re- and re-reinfections and types of available vaccines adjusted for various strains it's just a big mess now.
 
Last edited:
  • #38
I tend to agree that it is highly unlikely that recent vaccination will have no effect on transmission, but we need to revisit what we know about infectious diseases. The presence of antibodies in the blood is a considerable barrier to infection, the antibodies will bind to the virus, reducing the number of viable virus particles, while the immune system starts to ramp up production. The "little bundle of joy" that causes COVID-19, is of course an RNA virus and the reproduction of RNA viruses is inefficient to say the least, the virus compensates for this by a massive increase in its reproduction rate. This does mean that pre-existing antibodies can be quickly depleted as they bind to the new virus particles then if the number of viruses reach the level needed to cause symptoms occurs very rapidly, the immune system simply can't keep up. COVID-19 appears to have evolved in ways to ensure a very short incubation time, Omicron variants may become symptomatic within 1 or 2 days of infection.

As we appear to be almost totally dependent on pre-existing antibodies to prevent infection and the antibodies will be the ones that prevent cell entry, the first idea was to create a vaccine that would boost the antibodies to the ancestral strain and also promote antibodies to one of the newer variants. It was suggested that this would not only increase the range of the antibodies but would also boost the production of antibodies specific to the later strains, to a much higher level, the so-called bivalent vaccines. Initial studies did suggest that the levels achieved were much higher, but over time it became clear that this wasn't translating into significantly increased resistance to infection.
The latest idea is that the so-called "original antigenic sin" may mean that if a person is exposed to the original strain, as was used in the 1st vaccines, following a bivalent vaccine the immune system would preferentially produce antibodies to the original strain, effectively reducing the production of antibodies to the more recent strain. The new vaccine which should be available within a week or so is a monovalent vaccine targeting one of the Omicron variants. The hope is that this will stimulate much higher levels of more specific antibodies which should be more protective, the trouble is that this is "a hope", we will only know if this actually works after its introduction.
The approval of the monovalent vaccines has been based on the known safety profile of the mRNA vaccines, not evidence of its ability to induce the specific effects wanted. Of course, the effectiveness against severe disease should remain the same.
 
  • Informative
  • Like
Likes russ_watters, bhobba, OmCheeto and 1 other person
  • #39
I got this alert today

https://medicalxpress.com/news/2023-09-moderna-reveals-highly-covid-vaccine.html

These plus points:

  • Improved antigen expression: mRNA-1283 demonstrated improved antigen expression compared to the clinically available mRNA-1273, which encodes the full-length spike protein. This suggests that mRNA-1283 can produce higher levels of the target antigens.
  • Enhanced antibody responses: When administered as a primary series, booster, or variant-specific booster, mRNA-1283 elicited similar or greater immune responses than the original mRNA-1273.
  • Greater stability: mRNA-1283 showed greater stability at refrigerated temperatures (2° to 8°C). Specifically, mRNA-1283 reached 62% of its initial integrity at 12 months when stored at 2° to 8°C, while the original version reached 63% integrity after only six months under the same conditions, effectively doubling the shelf life.
  • Dose-sparing: mRNA-1283 demonstrated the ability to elicit effective immunogenic responses even at lower doses, suggesting the possibility of dose-sparing, which could reduce potential reactogenicity.
  • Protection against variants: mRNA-1283, including variant-specific versions, produced more significant neutralizing antibody (nAb) responses against variants such as B.1.351 and B.1.617.2 compared to mRNA-1273, indicating its effectiveness against emerging variants.

Abstract to a paper here. https://www.science.org/doi/10.1126/scitranslmed.adf4100
 
  • Like
  • Informative
Likes jim mcnamara and Tom.G
  • #40
Laroxe said:
As we appear to be almost totally dependent on pre-existing antibodies to prevent infection and the antibodies will be the ones that prevent cell entry,
Not quite: The ubiquitous first line defense by T cells that target non mutating viral proteins and up to 30 epitopes on virus most likely account for exposures by infected family members that do not result in seroconversion/antibodies. Or mild/asymptomatic infections , with antibodies. I am unvaccinated for SARS-CoV-2. However Im sure have been exposed many times especially in these crowded wet markets. https://www.science.org/doi/10.1126/science.abh1823
 
Last edited:
  • #41
Already a lot of threads on Covid so I will put this here if that is ok.

This article in phys.org today describes a study based on (ACE2) protein acting as a decoy for the virus. https://medicalxpress.com/news/2023-11-long-acting-biologic-transmucosal-properties-sars-cov-.html

There is a link to the paper in the article.

From the discussion in terms of the need for new treatments in addition to the vaccines.

“The low effectiveness of COVID-19 vaccines in specific patient groups, such as immunocompromised patients, along with the emergence of SARS-CoV-2 variants capable of evading vaccine-induced immunity, underlines the need for novel treatment approaches.”
 
  • Like
Likes Nik_2213
  • #42
Upside, caution, masking and vaccinations mean I've had neither Covid nor 'Flu during the pandemic.
Downside, this Autumn's UK Covid and Flu' boosters totally 'lit off' my immune system, gave me what felt like '3-day flu' then a week of severely streaming head-cold. (Generic anti-histamines mitigated the misery...)
I reckon I'd had enough residual immunity to the boosters' content to send my immune system on a rampage.

But, hey, a zillion times better than 'Blues & Twos', or being stuck 'Home Alone' with full-on fever and a clan of puzzled cats...
 

Similar threads

  • Biology and Medical
Replies
1
Views
899
  • Biology and Medical
Replies
3
Views
1K
Replies
2
Views
839
Replies
19
Views
1K
  • Biology and Medical
Replies
2
Views
1K
  • Biology and Medical
Replies
3
Views
2K
Replies
26
Views
2K
  • Biology and Medical
15
Replies
516
Views
27K
  • Biology and Medical
17
Replies
562
Views
26K
  • Biology and Medical
Replies
24
Views
2K
Back
Top